JP2003516354A - 生物学的利用率が向上し、個人間及び個人内の吸収偏差が狭められたイトラコナゾール含有組成物 - Google Patents

生物学的利用率が向上し、個人間及び個人内の吸収偏差が狭められたイトラコナゾール含有組成物

Info

Publication number
JP2003516354A
JP2003516354A JP2001543110A JP2001543110A JP2003516354A JP 2003516354 A JP2003516354 A JP 2003516354A JP 2001543110 A JP2001543110 A JP 2001543110A JP 2001543110 A JP2001543110 A JP 2001543110A JP 2003516354 A JP2003516354 A JP 2003516354A
Authority
JP
Japan
Prior art keywords
itraconazole
spray
containing composition
cellulose
solubility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001543110A
Other languages
English (en)
Japanese (ja)
Inventor
ジョン−ウォン ウォン
ジュン−ハン キム
ハン−シク ウォン
スン−ウォー ジャン
ウォーン−タク バエ
Original Assignee
ドン・ア・ファーム・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドン・ア・ファーム・カンパニー・リミテッド filed Critical ドン・ア・ファーム・カンパニー・リミテッド
Publication of JP2003516354A publication Critical patent/JP2003516354A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2001543110A 1999-12-08 1999-12-31 生物学的利用率が向上し、個人間及び個人内の吸収偏差が狭められたイトラコナゾール含有組成物 Withdrawn JP2003516354A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1019990055802A KR100694667B1 (ko) 1999-12-08 1999-12-08 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제
KR1999/55802 1999-12-08
PCT/KR1999/000854 WO2001041765A1 (ko) 1999-12-08 1999-12-31 Compositions containing itraconazole with improved bioavailability and narrow intra-individual and inter-individual variation of its absorption

Publications (1)

Publication Number Publication Date
JP2003516354A true JP2003516354A (ja) 2003-05-13

Family

ID=19624262

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001543110A Withdrawn JP2003516354A (ja) 1999-12-08 1999-12-31 生物学的利用率が向上し、個人間及び個人内の吸収偏差が狭められたイトラコナゾール含有組成物

Country Status (7)

Country Link
EP (1) EP1274432A4 (ko)
JP (1) JP2003516354A (ko)
KR (1) KR100694667B1 (ko)
CN (1) CN1398184A (ko)
AU (1) AU1896400A (ko)
CA (1) CA2393737A1 (ko)
WO (1) WO2001041765A1 (ko)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005521674A (ja) * 2002-02-01 2005-07-21 ディポメド，インコーポレイティド 即効性及び徐放性薬物をデリバリーする経口剤形の製造
JP2018502160A (ja) * 2015-01-20 2018-01-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 担体ポリマーとしてのポリビニルアルコールを用いた化合物の固体分散体

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010097244A (ko) * 2000-04-21 2001-11-08 유충식 위산도 비의존성 고용해도를 갖는 이트라코나졸 함유약학적 조성물 및 그 제조방법
KR100432949B1 (ko) * 2000-06-13 2004-05-31 코오롱제약주식회사 생체이용율이 향상된 이트라코나졸의 분립체 조성물과이를 이용한 이트라코나졸 제제 및 그 제조방법
KR100438485B1 (ko) * 2001-08-13 2004-07-09 한국디디에스제약 주식회사 아졸류 항진균제의 약제학적 조성물
KR100425755B1 (ko) * 2001-08-27 2004-04-03 주식회사 원진신약 이트라코나졸을 함유하는 조성물 및 그 제조방법
KR100441745B1 (ko) * 2001-11-30 2004-07-27 환인제약 주식회사 이트라코나졸의 경구투여용 조성물과 그 제조방법
WO2003063833A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
KR100557680B1 (ko) * 2002-11-23 2006-03-07 한국유나이티드제약 주식회사 이트라코나졸의 용해도 개선을 위한 펠렛제제 및 그제조방법
SI1438960T2 (sl) † 2003-01-14 2013-04-30 Cimex Pharma Ag Sestavek itrakonazola, dispergiranega v hidrofilnem polimeru, z izboljšano biorazpoloĹľljivostjo
ES2283725T5 (es) † 2003-01-14 2014-11-28 Acino Pharma Ag Composición bioequivalente de itraconazol dispersada en un polímero hidrófilo
HU227142B1 (en) * 2003-07-02 2010-08-30 Egis Gyogyszergyar Nyilvanosan Capsule of improved release containing fluconazole
WO2005011635A2 (en) 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
US20050058670A1 (en) * 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
CN1285590C (zh) * 2004-02-23 2006-11-22 上海医药工业研究院 伊曲康唑盐酸盐口服固体组合物和制备方法
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
KR100555794B1 (ko) * 2005-03-17 2006-03-03 삼천당제약주식회사 이트라코나졸을 함유하는 경구용 조성물
WO2007110878A1 (en) * 2006-03-27 2007-10-04 Panacea Biotec Ltd Sustained release pharmaceutical composition on the basis of a release system comprising an acid-soluble polymer and a ph-dependent polymer.
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
GB0814953D0 (en) * 2008-08-18 2008-09-24 Unilever Plc Improvements relating to nanodisperse compositions
KR101374854B1 (ko) 2009-05-27 2014-03-19 주식회사 삼양바이오팜 생체이용률이 향상된 난용성 약물 함유 미립구 및 그 제조 방법
CN102309488A (zh) * 2010-07-02 2012-01-11 北京京卫燕康药物研究所有限公司 一种伊曲康唑药物组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
CA2258683C (en) * 1996-06-28 2007-07-31 Schering Corporation Oral composition comprising a triazole antifungal compound
FR2758461A1 (fr) * 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
KR19990055802A (ko) * 1997-12-27 1999-07-15 김영환 반도체소자 제조방법
PT1039909E (pt) * 1997-12-31 2003-02-28 Choongwae Pharma Corp Metodo de producao e composicao de uma preparacao oral de itraconazole
KR100288890B1 (ko) * 1997-12-31 2001-05-02 최현식 이트라코나졸 경구용 제제 및 그의 제조방법
ID29270A (id) * 1998-11-20 2001-08-16 Rtp Pharma Inc Partikel-partikel mikro yang distabilkan oleh fosfolipid yang dapat menyebar

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005521674A (ja) * 2002-02-01 2005-07-21 ディポメド，インコーポレイティド 即効性及び徐放性薬物をデリバリーする経口剤形の製造
JP2018502160A (ja) * 2015-01-20 2018-01-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 担体ポリマーとしてのポリビニルアルコールを用いた化合物の固体分散体

Also Published As

Publication number Publication date
EP1274432A1 (en) 2003-01-15
WO2001041765A1 (ko) 2001-06-14
KR100694667B1 (ko) 2007-03-14
AU1896400A (en) 2001-06-18
CA2393737A1 (en) 2001-06-14
EP1274432A4 (en) 2004-11-10
KR20010054823A (ko) 2001-07-02
CN1398184A (zh) 2003-02-19

Similar Documents

Publication Publication Date Title
JP2003516354A (ja) 生物学的利用率が向上し、個人間及び個人内の吸収偏差が狭められたイトラコナゾール含有組成物
JP7211644B2 (ja) ニロチニブの医薬組成物
EP2395979B1 (en) Delayed release, oral dosage compositions that contain amorphous cddo-me
EP1318788B1 (en) Solid dose nanoparticulate compositions
JP4860469B2 (ja) 新規シルデナフィル遊離塩基組成物
JP5288791B2 (ja) 難水溶性物質含有微細化組成物
JPH11509238A (ja) 向上した生物学的利用性を有する抗菌性組成物
JP2001515029A (ja) 粒状分散形態の固形医薬剤形
KR20100047848A (ko) 디히드로피리딘 칼슘 채널 길항제를 함유하는 약제학적 조성물 및 그것의 제조방법
JP3967924B2 (ja) 溶出性の改善されたプランルカスト固体分散系及びその製造方法
JP2018538329A (ja) セレコキシブおよびその塩および誘導体の複合体、その調製のためのプロセスおよびそれらを含有する医薬組成物
TW200911303A (en) Powders for reconstitution
JP2000500477A (ja) 即時放出型の薬学的組成物
WO2013024373A1 (en) Pharmaceutical composition comprising cefuroxime
WO2006018814A2 (en) Oral liquid suspensions of metaxalone
JP2020510625A (ja) セレコキシブを含有する医薬組成物
EP2802311B1 (en) Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
WO2021080529A1 (en) Solid pharmaceutical formulations comprising ticagrelor
WO2001085135A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ITRACONAZOLE WITH GASTRIC pH-INDEPENDENTLY IMPROVED SOLUBILITY AND PREPARATION METHOD THEREOF
EP3644968A1 (en) Levocloperastine fendizoate suspension having enhanced dissolution and resuspendability
KR102306856B1 (ko) 용출률 및 경구 흡수율이 개선된 셀레콕시브 고체 분산체 및 이의 제조방법
EP3305282A2 (en) Composition of pranlukast-containing solid preparation with improved bioavailability and method for preparing same
US20230218582A1 (en) Losartan liquid formulations and methods of use
KR100818701B1 (ko) 이부프로펜 경구용 고형제제 조성물
AU2020329628A1 (en) Low-dosage orodispersible opioid tablet and method for preparing same

Legal Events

Date Code Title Description
A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20041215

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20041215